More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena expects $66.5M in milestone payments from marketing and distribution partner Eisai in 2013, $6M from amortization of upfront payments, and $3M from manufacturing services from Siegfried. Arena also expects R&D costs of $70-78M and G&A expenses of $28-34M. (PR)